Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 1/2006

01-02-2006 | Letter

Infliximab as monotherapy in giant cell arteritis

Authors: Imad Uthman, Nadim Kanj, Samir Atweh

Published in: Clinical Rheumatology | Issue 1/2006

Login to get access

Excerpt

Corticosteroids are highly effective in suppressing systemic inflammation of giant cell arteritis (GCA); however, the long-term use of these agents is associated with many complications prompting their discontinuation [1, 2]. We herein report a case of GCA successfully treated with infliximab [monoclonal antibody to tumor necrosis factor-α (TNF-α)] monotherapy. …
Literature
1.
Weyand CM, Goronzy JJ (2003) Giant-cell arteritis and polymyalgia rheumatica. Ann Intern Med 139:505–515PubMed
2.
Nesher G, Sonnenblick M, Friedlander Y (1994) Analysis of steroid related complications and mortality in temporal arteritis: a 15-year survey of 43 patients. J Rheumatol 21:1283–1286PubMed
3.
Field M, Cook A, Gallagher G (1997) Immuno-localisation of tumour necrosis factor and its receptors in temporal arteritis. Rheumatol Int 17:113–118CrossRefPubMed
4.
Weyand CM, Fulbright JW, Hunder GG, Evans JM, Goronzy JJ (2000) Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum 43:1041–1048CrossRefPubMed
5.
Hernandez-Rodriguez J, Garcia-Martinez A, Casademont J, Filella X, Esteban MJ, Lopez-Soto A et al (2002) A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. Arthritis Rheum 47:29–35CrossRefPubMed
6.
Hernandez-Rodriguez J, Segarra M, Vilardell C, Sanchez M, Garcia-Martinez A, Esteban MJ et al (2004) Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology (Oxford) 43:294–301
7.
Uthman I, Mroueh K, Arayssi T, Nasr F, Masri AF (2004) The use of tumor necrosis factor neutralization strategies in rheumatologic disorders other than rheumatoid arthritis in Lebanon. Semin Arthritis Rheum 33:422–423CrossRefPubMed
8.
Andonopoulos AP, Meimaris N, Daoussis D, Bounas A, Giannopoulos G (2003) Experience with infliximab (anti-TNF alpha monoclonal antibody) as monotherapy for giant cell arteritis. Ann Rheum Dis 62:1116CrossRefPubMed
9.
Cantini F, Niccoli L, Salvarani C, Padula A, Olivieri I (2001) Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum 44:2933–2935CrossRefPubMed
10.
Rozin AP, Andonopoulos AP, Meimaris N, Daoussis D, Bounas A, Giannopoulos G (2004) Infliximab efficiency and failure (Authors’ reply). Ann Rheum Dis 63:751–752PubMed
Metadata
Title
Infliximab as monotherapy in giant cell arteritis
Authors
Imad Uthman
Nadim Kanj
Samir Atweh
Publication date
01-02-2006
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 1/2006
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-005-1115-8

Other articles of this Issue 1/2006

Clinical Rheumatology 1/2006 Go to the issue

Case Report

Rheumatoid arthritis in a patient with common variable immunodeficiency:difficulty in diagnosis and therapy

Case Report

Emergence of manifestations of HIV infection in a case of systemic lupus erythematosus following treatment with IV cyclophosphamide

Case Report

Eosinophilic fasciitis associated with autoimmune phenomena after bone marrow transplantation: report of two cases

Original Article

Measuring utilities by the time trade-off method in Tunisian rheumatoid arthritis patients

Letter

Acute pseudogout following contrast angiography

Original Article

Perinuclear antineutrophil cytoplasmic antibody myeloperoxidase-positive vasculitis in association with ulcerative colitis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits